What were Danaher’s (NYSE:DHR) net earnings and earnings per share (EPS) for Q1 2026?

Danaher reported net earnings of $1 billion, or $1.45 per diluted share on a GAAP basis, for Q1 2026. On a non-GAAP basis, adjusted diluted EPS grew 9.5% to $2.06, comfortably exceeding analyst expectations.

How did Danaher’s adjusted earnings per share (EPS) perform in Q1 2026 compared to expectations?

Danaher’s adjusted EPS grew by 9.5% to $2.06, surpassing analyst expectations and indicating significant operating leverage within its business units.

What major announcement did Danaher make in Q1 2026?

Danaher announced its intention to acquire Masimo, a global leader in noninvasive monitoring technologies and hospital automation. This acquisition will help Danaher expand its footprint in high-acuity clinical environments and enhance its digital health offerings.

How does the Masimo acquisition fit into Danaher's overall strategy?

The acquisition of Masimo is strategically aligned with Danaher's goal of strengthening its diagnostics portfolio and creating a more comprehensive clinical workflow solution through the integration of Masimo’s sensing technology.

Image for illustrative purposes only. Not a real photo.

Danaher delivers robust Q1 2026 results and announces strategic move

Written by Brie CarterPublished Apr 21, 2026, 12:00 AMLast Updated Jul 7, 2026, 6:15 AM

Danaher (NYSE:DHR) today reported financial results for the first quarter ended March 31, 2026, characterized by robust cash flow generation and a landmark announcement regarding its portfolio expansion.

The company reported net earnings of $1 billion, or $1.45 per diluted share on a GAAP basis.

The company’s top-line performance saw revenues rise 3.5% to $6 billion, reflecting steady demand across its core life sciences and diagnostics segments.

On a non-GAAP basis, adjusted diluted earnings per share grew 9.5% to $2.06, comfortably exceeding analyst expectations and demonstrating significant operating leverage within its business units.

In a move that defined the quarter's results, Danaher announced its intention to acquire Masimo, a global leader in noninvasive monitoring technologies and hospital automation.

This acquisition is a mechanical necessity for Danaher as it seeks to deepen its footprint in high-acuity clinical environments and expand its digital health offerings.

The integration of Masimo’s sensing technology is expected to complement Danaher’s existing diagnostics portfolio, creating a more comprehensive clinical workflow solution.

Danaher’s cash flow remains a pillar of its corporate strategy.

The company generated $1.3 billion in operating cash flow during the first quarter, with non-GAAP free cash flow reaching $1.1 billion.

This liquidity position provides the capital required to pursue large-scale M&A while continuing to invest in internal research and development.

Buoyed by the first-quarter performance and the anticipated contributions from its strategic initiatives, management has raised its full-year 2026 adjusted EPS guidance to a range of $8.35 to $8.55.

Furthermore, the company expects non-GAAP core revenue growth of 3% to 6% for the full year.